Perspective Therapeutics Q4 revenue falls 35% to $1.84M, net loss $2.9M; merger completed

Perspective Therapeutics, Inc.

Revenue down 35% YoY to $1.84M; prostate brachytherapy sales dropped 50% due to lost largest customer orders.
Net loss $2.9M ($0.02/share) vs $1.6M ($0.01) last year; operating expenses rose to $3.7M from $2.86M.
Gross margin plunged to 22.0% from 43.3%, driven by lower prostate sales volume.
Cash & equivalents $43.8M, no debt; stockholders' equity $55.0M.
Completed merger with Viewpoint Molecular Targeting on Feb 3; name changed to Perspective Therapeutics; ticker to CATX on Feb 21.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Perspective Therapeutics, Inc. reported the three months ended December 31, 2022 results: revenue $1.84 million.

Period: the three months ended December 31, 2022
Revenue: $1.84 million
Result: reported results

Exact text from the filing

Revenue for the three months ended December 31, 2022 decreased 35% to $1.84 million versus $2.82 million in the prior year comparable period.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-003637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.